Abstract
Many new approaches involving biological agents have given promising results in experimental HD models. Clinical trials with immunotoxins, IL-2, Bi-Moabs or radioimmunoconjugates have demonstrated some clinical efficacy in patients with advanced refractory HD. Although it looks very unlikely to cure patients with larger tumour masses by either of these approaches, it might be feasible to treat bulky disease by conventional therapy first and then administer biological drugs to kill residual H-RS cells. Future phase-III trials will have to prove a possible superior effect of this combined immuno-/chemotherapy. In the meantime, the search for the most promising approach continues.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Anti-Idiotypic / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Diphtheria Toxin / therapeutic use
-
Forecasting
-
Hodgkin Disease / drug therapy
-
Hodgkin Disease / immunology
-
Hodgkin Disease / radiotherapy
-
Hodgkin Disease / therapy*
-
Humans
-
Immunoconjugates / therapeutic use
-
Immunotoxins / therapeutic use
-
Interleukin-2 / therapeutic use
-
Ki-1 Antigen / immunology
-
Killer Cells, Natural / immunology
-
Lymphocyte Activation
-
N-Glycosyl Hydrolases*
-
Plant Proteins / therapeutic use
-
Prodrugs / therapeutic use
-
Radioimmunotherapy
-
Ribosome Inactivating Proteins, Type 1
-
Ricin / therapeutic use
-
Saporins
-
T-Lymphocytes / immunology
Substances
-
Antibodies, Anti-Idiotypic
-
Antibodies, Monoclonal
-
Diphtheria Toxin
-
Immunoconjugates
-
Immunotoxins
-
Interleukin-2
-
Ki-1 Antigen
-
Plant Proteins
-
Prodrugs
-
Ribosome Inactivating Proteins, Type 1
-
Ricin
-
N-Glycosyl Hydrolases
-
Saporins